Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment

J Am Acad Dermatol. 2019 Feb;80(2):577-578. doi: 10.1016/j.jaad.2018.09.016. Epub 2018 Sep 20.
No abstract available

Publication types

  • Editorial
  • Review

MeSH terms

  • Adult
  • Child
  • Dermatologic Agents / therapeutic use*
  • Dermatology
  • Drug Approval / legislation & jurisprudence
  • Female
  • Health Services Accessibility*
  • Humans
  • Male
  • Needs Assessment
  • Off-Label Use / legislation & jurisprudence*
  • Skin Diseases / drug therapy*
  • Skin Diseases / pathology
  • United States
  • United States Food and Drug Administration / legislation & jurisprudence*

Substances

  • Dermatologic Agents